{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:47:56Z","timestamp":1763578076492,"version":"3.45.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15557"],"award-info":[{"award-number":["23K15557"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ground-glass opacity (GGO) component is a favourable prognostic factor in non-small cell lung cancer (NSCLC), whereas NSCLC with interstitial lung abnormalities (ILA) generally has poorer prognoses. We investigated the clinical significance of GGO in patients with NSCLC and ILA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 1319 patients who underwent pulmonary resection for clinical stage IA NSCLC at 2 institutions between 2010 and 2020, we retrospectively assessed 216 patients with ILA based on preoperative CT. Patients were divided into 2 groups: pure solid tumours without GGO and subsolid tumours with GGO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 216 patients with ILA, 146 (68%) had pure solid tumours and 70 (32%) had subsolid tumours. Subsolid tumours had significantly better prognoses than pure solid tumours (5-year overall survival, 69.7% vs 48.6%, P\u2009=\u2009.0008; 5-year recurrence-free survival, 69.7% vs 42.3%, P\u2009&amp;lt;\u2009.0001). Recurrence occurred in 4 patients (6%) with subsolid tumours and 41 (28%) with pure solid tumours. Although the 5-year cumulative incidence of lung cancer deaths was significantly lower in subsolid tumours than in those with pure solid tumours (2.6% vs 23.6%, P\u2009=\u2009.0011), an increase in other causes of mortality after 2\u2009years post-surgery in subsolid tumours resulted in a comparable 5-year cumulative incidence of other causes of death (28.4% vs 36.1%, P\u2009=\u2009.260).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In clinical stage IA NSCLC with ILA, subsolid tumours have a lower lung cancer mortality than pure solid tumours; however, higher other-cause mortality after 2\u2009years contributes to poorer overall survival. Optimizing comorbidity management may improve long-term prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/icvts\/ivaf260","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:14:19Z","timestamp":1761830059000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Ground-Glass Opacity in Clinical Stage IA Non-Small Cell Lung Cancer With Interstitial Lung Abnormalities"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-1709","authenticated-orcid":false,"given":"Norifumi","family":"Tsubokawa","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-8551,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-8928","authenticated-orcid":false,"given":"Takahiro","family":"Mimae","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-8551,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-4833","authenticated-orcid":false,"given":"Takeshi","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center , Kure 737-0023,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-4349","authenticated-orcid":false,"given":"Atsushi","family":"Kagimoto","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center , Kure 737-0023,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3321-2443","authenticated-orcid":false,"given":"Atsushi","family":"Kamigaichi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-8551,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-8551,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-3828","authenticated-orcid":false,"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-8551,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025111913321393900_ivaf260-B1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","article-title":"Association between interstitial lung abnormalities and all-cause mortality","volume":"315","author":"Putman","year":"2016","journal-title":"JAMA"},{"key":"2025111913321393900_ivaf260-B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The impact of lung cancer on survival of idiopathic pulmonary fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest"},{"key":"2025111913321393900_ivaf260-B3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jtcvs.2017.03.116","article-title":"Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease","volume":"154","author":"Tsutani","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025111913321393900_ivaf260-B4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2025111913321393900_ivaf260-B5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"2025111913321393900_ivaf260-B6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"2025111913321393900_ivaf260-B7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.athoracsur.2022.05.069","article-title":"Complications and survival after lung cancer resection in interstitial lung disease","volume":"115","author":"Fujiwara","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"2025111913321393900_ivaf260-B8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.jtcvs.2013.09.050","article-title":"Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer","volume":"147","author":"Sato","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025111913321393900_ivaf260-B9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtcvs.2012.11.019","article-title":"Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings","volume":"146","author":"Tsutani","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025111913321393900_ivaf260-B10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jtcvs.2020.01.107","article-title":"Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer","volume":"161","author":"Hattori","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025111913321393900_ivaf260-B11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.athoracsur.2016.08.074","article-title":"Concomitant interstitial lung disease is a risk factor for pleural invasion in lung cancer","volume":"103","author":"Hata","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"2025111913321393900_ivaf260-B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025111913321393900_ivaf260-B13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2025111913321393900_ivaf260-B14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtho.2017.11.129","article-title":"Influence of ground glass opacity and the corresponding pathological findings on survival in patients with clinical stage I non-small cell lung cancer","volume":"13","author":"Aokage","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025111913321393900_ivaf260-B15","doi-asserted-by":"crossref","first-page":"ezac166","DOI":"10.1093\/ejcts\/ezac166","article-title":"The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer","volume":"62","author":"Kamigaichi","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025111913321393900_ivaf260-B16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.athoracsur.2019.01.079","article-title":"Ground-glass opacity is a strong prognosticator for pathologic stage IA lung adenocarcinoma","volume":"108","author":"Miyoshi","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2025111913321393900_ivaf260-B17","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","article-title":"Development and progression of interstitial lung abnormalities in the Framingham heart study","volume":"194","author":"Araki","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025111913321393900_ivaf260-B18","doi-asserted-by":"crossref","first-page":"ezac291","DOI":"10.1093\/ejcts\/ezac291","article-title":"Parsimonious risk model for predicting mortality after surgical lung biopsy for interstitial lung disease","volume":"62","author":"Yun","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025111913321393900_ivaf260-B19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cllc.2024.01.003","article-title":"Clinical significance of preserving pulmonary function after lung resection in early-stage non-small-cell lung cancer","volume":"25","author":"Tsubokawa","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2025111913321393900_ivaf260-B20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"2025111913321393900_ivaf260-B21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s11748-024-02037-7","article-title":"Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities","volume":"72","author":"Tsubokawa","year":"2024","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2025111913321393900_ivaf260-B22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S2213-2600(23)00041-3","article-title":"Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial","volume":"11","author":"Aokage","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025111913321393900_ivaf260-B23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"key":"2025111913321393900_ivaf260-B24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/jjco\/hyaa092","article-title":"Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, Surprise)","volume":"50","author":"Tanaka","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025111913321393900_ivaf260-B25","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025111913321393900_ivaf260-B26","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2025111913321393900_ivaf260-B27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"2025111913321393900_ivaf260-B28","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111913321393900_ivaf260-B29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/icvts\/ivac014","article-title":"Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function","volume":"34","author":"Mimae","year":"2022","journal-title":"Interact CardioVasc Thorac Surg"}],"container-title":["Interdisciplinary CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/icvts\/advance-article-pdf\/doi\/10.1093\/icvts\/ivaf260\/65050263\/ivaf260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/40\/11\/ivaf260\/65050263\/ivaf260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/40\/11\/ivaf260\/65050263\/ivaf260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:32:16Z","timestamp":1763577136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/doi\/10.1093\/icvts\/ivaf260\/8307533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivaf260","relation":{},"ISSN":["2753-670X"],"issn-type":[{"type":"electronic","value":"2753-670X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,31]]},"article-number":"ivaf260"}}